Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells.

@article{Weber2012DualPA,
  title={Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells.},
  author={Christoph Weber and Thiemo B Schreiber and Henrik Daub},
  journal={Journal of proteomics},
  year={2012},
  volume={75 4},
  pages={1343-56}
}
Small molecule inhibitors of protein kinases have emerged as a major class of therapeutic agents for the treatment of hematological malignancies. Both in vitro studies and patient case reports suggest therapeutic potential of the clinical kinase inhibitors erlotinib and gefitinib in acute myeloid leukemia (AML). The drugs' cellular modes of action in AML warrant further investigation as their primary therapeutic target, the epidermal growth factor receptor, is not expressed. We therefore… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
29 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 29 extracted citations

Similar Papers

Loading similar papers…